Abstract:
The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein ring A, B1, B2, B3, L, R1, R4, R5 and m of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.
Abstract:
Control and feature systems for processing signals from a satellite positioning system include an expert system receiver manager; a joint detection, carrier centering and bit sync acquisition subsystem; peak detection; a multi-dimensional measurement interpolation subsystem; a system for mode switching between a navigational signal; and power control module for receiver.
Abstract:
Clamping forceps and associated methods are provided that generally include a head section including first and second clamp members configured to cooperatively clamp so as to at least partially encircle a tumor or other structure, an elongated body section in cooperation with the head section, and a clamping mechanism at least partially movably mounted with respect to the elongated body section. The clamping forceps may include a control mechanism for variably controlling the clamping force, at least one sensor mounted with respect to the clamp member(s), means for fixating the clamp member(s) relative to tissue, the first and second clamp members structured to define a variable perimeter extent, and a clamping mechanism which accommodates variable rates of clamping action. Actuation of the clamping mechanism generally maintains substantially parallel actuation of the first and second clamp members with respect to the tumor or the other anatomical structure. Methods for use of the clamping forceps may include introducing the head section to the surgical site through an incision; positioning a trocar port at the surgical site; introducing at least a portion of the elongated body section to the surgical site through the trocar port; intra-corporeally connecting the head section with respect to the elongated body section; and extra-corporeally actuating the clamping mechanism so as to actuate the first and second clamp members into a clamping position around the tumor or other anatomical structure.
Abstract:
A Krueger, or leading edge flap, deployable from a lower aerodynamic surface of an aircraft main wing element so as to form a slot between the Krueger and the main wing element when deployed, the deployed Krueger having a leading edge, a trailing edge and upper and lower aerodynamic surfaces extending between the leading edge and the trailing edge, and a flow deflector which provides an effectively divergent flap profile thickness in the downstream direction at or adjacent the Krueger trailing edge so as to direct airflow away from the lower aerodynamic surface of the deployed Krueger towards an upper aerodynamic surface of the main wing element. Also, aircraft wing assembly including a main wing element and the Krueger.
Abstract:
A hand-held dispensing applicator includes a source of fluid, a frangible applicator tip attached to the fluid source, and an absorbent member attached to the frangible applicator tip. When broken, fluid flows from the source to the absorbent member, whereby the fluid is applied and spread on a surface. In one embodiment, the dispensing applicator comprises a support element permanently connected to the fluid source, a relatively rigid tongue element extending outwardly of the support element, and a frangible region there between. Optionally, the tongue element comprises ribs for reinforcing the tongue element to resist unintentional breaking of the frangible region. Also optionally, the applicator tip includes a semi-permeable or non-permeable partial shield member disposed around the frangible region to control the speed and direction of the dispersion of the fluid in the absorbent member. Adaptive embodiments allow the generation of designs applicable to a particular medical purpose.
Abstract:
The bearing cage has a first flange, a second flange, and a plurality of cage bars extending between the first flange and the second flange so as to form and define outer boundaries for a plurality of pockets. The first flange and the second flange are each bent inward toward the pocket and then extend parallel in a vertical direction, forming a contact surfaces. The contact surfaces are in contact at each end of the rollers arranged in the pocket. The contact surfaces of the bearing cage present a large contact area between the ends of the rollers and the ends of the pockets where there is a lubricant film. Also, the surface of the contact surfaces is smooth.
Abstract:
Compounds of Formula I are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.
Abstract:
The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula (I); wherein ring A, B1, B2, B3, L, R1, R2, ring Z, m and n of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula (I), intermediates and processes useful for the preparation of compounds of Formula (I).